Servier Buys Edgewise Muscular Dystrophy Business for Up to $2.65 Billion
Updated
Updated · Pharmaceutical Executive · Jun 1
Servier Buys Edgewise Muscular Dystrophy Business for Up to $2.65 Billion
13 articles · Updated · Pharmaceutical Executive · Jun 1
$1.55 billion upfront plus up to $1.1 billion in milestones will give Servier control of Edgewise Therapeutics' muscular dystrophy business, with closing expected in the third quarter of 2026.
The acquisition centers on sevasemten, an investigational oral fast skeletal myosin inhibitor being tested in a pivotal Becker muscular dystrophy cohort and a Phase II Duchenne muscular dystrophy trial.
Servier said the deal supports its push into rare neuromuscular disorders and advances its Servier 2030 neurology strategy, while also bringing over the associated team and capabilities.
The move comes amid broader biotech dealmaking this week, including Eli Lilly's up-to-$1.26 billion Hanmi licensing pact and Avenzo's $215 million merger-backed public listing plan.
Will Servier's $2.65B bet on sevasemten yield the first targeted therapy for Becker muscular dystrophy?
Why is Eli Lilly betting over a billion dollars on a rare gut disorder treatment?
Are Avenzo's next-generation antibody-drug conjugates the future of personalized cancer therapy?
Servier’s $2.65 Billion Acquisition of Edgewise’s Muscular Dystrophy Program: Sevasemten’s Promise and the Race to Transform Rare Disease Treatment
Overview
Servier has taken a major step in its strategy to expand in neurology and rare diseases by acquiring Edgewise Therapeutics' muscular dystrophy business. This deal brings Servier promising assets, especially the oral drug sevasemten, and an experienced team, allowing the company to enter critical areas like Becker and Duchenne muscular dystrophy. The acquisition supports Servier’s goal to provide targeted therapies for patients with rare, debilitating conditions that currently have limited treatment options. With this move, Servier strengthens its position as a key player in neuromuscular disorders and advances its long-term ambition for growth in specialized medicine.